Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.
Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT.
Wiczer TE, et al. Among authors: mousa l.
Blood Adv. 2017 Sep 8;1(20):1739-1748. doi: 10.1182/bloodadvances.2017009720. eCollection 2017 Sep 12.
Blood Adv. 2017.
PMID: 29296820
Free PMC article.